The National Lipid Association has issued a position statement recommending the use of icosapent ethyl for treating patients with atherosclerotic CVD or type 2 diabetes, rooting its endorsement in the positive results of the REDUCE-IT study.
Apple announced the initiation of three new large-scale medical studies, including one focused on women’s health, one focused on hearing and one focused on cardiovascular health and movement.
Motivational text messages could be the key to better glycemic control in patients with both diabetes mellitus and coronary heart disease, according to research out of China.
SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events.
A multi-country study in Asia has revealed patients with both type 2 diabetes and heart failure face higher odds of structural CV abnormalities, a poorer quality of life and an increased risk of death.
An August 19 science advisory from the AHA states that a 4-gram dose of prescription omega-3 fatty acid medication can greatly reduce people’s triglyceride levels, but patients likely won’t see the same results if they turn to popular—yet unproven—fish oil therapies.
Advances in diabetes care over the past decade haven’t translated into better patient outcomes, researchers at Massachusetts General Hospital have found, with just one in four U.S. adults with the disease meeting treatment goals between 2005 and 2016.
People who ate the most plant-based foods in a recent Journal of the American Heart Association study were 32% less likely than their counterparts to die from heart disease later down the line.
Overall exposure to ionizing radiation for patients undergoing radiofrequency ablation of AFib is “acceptable” in most cases, according to research published in the American Journal of Cardiology—but obese patients are exposed to a higher dose than their normal-weight counterparts.
In patients with both type 2 diabetes and an elevated cardiovascular risk, metformin lowers the risk of all-cause mortality but does little to protect against CV death, MI or ischemic stroke, a new evaluation of the SAVOR-TIMI 53 trial has found.
